Biodexa Pharmaceuticals granted extension to regain compliance with Nasdaq

Biodexa Pharmaceuticals announced that a Nasdaq Hearings Panel has granted the company’s request for an extension of time to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq Stock Market set forth in Nasdaq Listing Rule 5550. As a condition of the panel’s decision, the company is required to demonstrate compliance with the minimum bid price requirement by evidencing a closing bid price of at least $1.00 per share for a minimum of 20 consecutive trading days by October 31.